Form 8-K Krystal Biotech, Inc. For: Nov 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Krystal Biotech (KRYS) PT Raised to $206 at Citi
November 4, 2024 4:42 PM ESTCiti analyst Carly Kenselaar raised the price target on Krystal Biotech (NASDAQ: KRYS) to $206.00 (from $204.00) while maintaining a Neutral rating.
The analyst comments "Though Vyjuvek sales of $83.8M were in-line vs. Citi/consensus of $82.3M/$83.4M, key risks associated with our... More
